Skip to content
Inciteful Med

Future Treatments & Clinical Trials: A Reason for Hope

Last updated:

Researchers are developing new "disease-modifying" treatments like ASOs and CRISPR that target the root cause of myotonic dystrophy—toxic RNA. While a cure is not yet available, joining patient registries is the best way to get involved in clinical trials for these promising therapies.

Key Takeaways

  • • New therapies for myotonic dystrophy aim to target the root cause of the disease by destroying the toxic RNA that traps essential cellular proteins.
  • • Antisense Oligonucleotides (ASOs) like DYNE-101 and AOC 1001 act as molecular erasers to eliminate toxic RNA and restore normal cell function.
  • • CRISPR gene editing is being studied in laboratories as a potential way to permanently remove the expanded repeats from the DNA.
  • • Researchers are evaluating repurposed medications like metformin and pitolisant to help manage symptoms such as walking difficulties and daytime sleepiness.
  • • Joining a patient registry like the Myotonic Dystrophy Family Registry is the most effective way to become eligible for upcoming clinical trials.

For the first time in the history of Myotonic Dystrophy, researchers are testing treatments that target the root cause of the disease, not just the symptoms [1]. While we do not yet have a cure, the scientific community is making massive strides toward “disease-modifying” therapies that could change the future of how this condition is managed [2].

RNA Therapies: Molecular Erasers

As you learned in the biology section, Myotonic Dystrophy is caused by “toxic RNA” that acts like a sponge, soaking up important proteins [3]. New drugs called Antisense Oligonucleotides (ASOs) are being developed to fix this [4].

Think of an ASO as a “molecular eraser.” It is a small piece of synthetic DNA or RNA that travels into your cells, finds the toxic expanded repeats, and marks them for destruction [1]. Once the toxic RNA is erased, the trapped proteins (MBNL) are freed to do their normal jobs again, allowing the cell to function properly [1][2].

Leading Therapies in Clinical Trials

Several drugs have received “Breakthrough Therapy” or “Fast Track” designation from the FDA, meaning they are being moved through the testing process as quickly and safely as possible.

  • DYNE-101: This therapy uses a specialized delivery system called the FORCE platform to carry the “eraser” drug directly into muscle cells, including the heart and diaphragm [4][5].
  • Delpacibart edetesiran (AOC 1001): This drug uses antibodies—special proteins that act like a GPS—to deliver the RNA-targeting drug specifically to muscle tissue [1]. Early trials have shown that this drug can successfully reduce toxic RNA levels and improve how cells process genetic information (splicing) [1].

CRISPR: Permanent Gene Editing

While ASOs must be taken regularly, CRISPR-Cas9 is being studied as a way to permanently fix the DNA. Researchers are using CRISPR as “molecular scissors” to cut out the expanded repeats from the DNA itself [6]. This research is currently in the laboratory and early animal-model stages, as scientists work to ensure it can be delivered safely to the whole body without causing unintended changes to other parts of your DNA [7][8].

Repurposed Drugs

Researchers are also looking at existing drugs to see if they can help DM symptoms:

  • Metformin: Typically used for diabetes, a small Phase 2 study found that metformin might help some adult DM1 patients walk longer distances by improving muscle metabolism [9][10].
  • Pitolisant: A drug used for narcolepsy that is being studied to see if it can help the “central” daytime sleepiness common in Myotonic Dystrophy [2].

Paving the Way for DM2

Most advanced clinical trials are currently focused on DM1 because the genetic cause is more uniform and well-studied [2]. However, because DM1 and DM2 share the same “toxic RNA” mechanism, the technology being developed for DM1 is expected to serve as a roadmap for future DM2 treatments [11].

How to Get Involved: Patient Registries

The most important thing a patient can do to support research is to join a Patient Registry, such as the Myotonic Dystrophy Family Registry [12].

  • Visibility: Researchers use registries to find patients who match the criteria for new trials [13].
  • Natural History: Registries help scientists understand how the disease changes over time (Natural History), which is essential for proving to the FDA that a new drug actually works [14][15].

By participating in a registry, you are not just a patient; you are an essential partner in the race for a cure [16].

Frequently Asked Questions

What are ASO treatments for myotonic dystrophy?
Antisense Oligonucleotides (ASOs) are new drugs that act like molecular erasers. They target and destroy the toxic RNA that causes myotonic dystrophy, freeing up important proteins so cells can function normally.
Can CRISPR gene editing cure myotonic dystrophy?
Researchers are studying CRISPR as a way to permanently fix the genetic mutation that causes myotonic dystrophy. While early laboratory research is promising, it is not yet available as a cure and still requires extensive testing for safety and effectiveness in humans.
Why are most clinical trials focused on DM1 instead of DM2?
Most advanced clinical trials currently focus on Myotonic Dystrophy Type 1 (DM1) because its genetic cause is more uniform and heavily studied. However, since both types share the same toxic RNA mechanism, the technology developed for DM1 is expected to help create future treatments for DM2.
Are there existing drugs that can help with myotonic dystrophy symptoms?
Yes, researchers are studying existing, repurposed drugs to manage symptoms. For example, metformin is being studied to see if it improves muscle metabolism and walking distance, while pitolisant is being tested for excessive daytime sleepiness.
How can I join a myotonic dystrophy clinical trial?
The best way to get involved in research is to join a patient registry, such as the Myotonic Dystrophy Family Registry. Researchers use these registries to find patients who match the specific criteria for new clinical trials and natural history studies.

Questions for Your Doctor

  • • Based on my genetic report, would I meet the eligibility criteria (such as repeat count) for current ASO trials like DYNE-101 or delpacibart edetesiran (AOC 1001)?
  • • Are there any 'Natural History' studies or registries I should join to help prepare for future clinical trials?
  • • Given the early research on metformin for walking distance, is that a repurposed drug we should consider as part of my care plan?
  • • If I am interested in a clinical trial, what baseline tests (like EKGs or breathing tests) do I need to have updated?
  • • What is the current status of research for Myotonic Dystrophy Type 2 (DM2), and how will the technology from DM1 trials eventually help DM2 patients?

Questions for You

  • • Have I signed up for the Myotonic Dystrophy Family Registry to ensure I am notified when a trial is looking for someone with my profile?
  • • Is my priority finding a 'disease-modifying' treatment (one that targets the cause) or finding better ways to manage my current symptoms like sleepiness or stiffness?
  • • Am I comfortable with the risks and frequent monitoring required to participate in an early-phase (Phase 1 or 2) clinical trial?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

    Johnson NE, Tai LJ, Hamel JI, et al.

    The New England journal of medicine 2026; (394(8)):763-772 doi:10.1056/NEJMoa2407326.

    PMID: 41707138
  2. 2

    The myotonic dystrophy type 1 drug development pipeline: 2022 edition.

    Pascual-Gilabert M, Artero R, López-Castel A

    Drug discovery today 2023; (28(3)):103489 doi:10.1016/j.drudis.2023.103489.

    PMID: 36634841
  3. 3

    Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

    LoRusso S, Weiner B, Arnold WD

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018; (15(4)):872-884 doi:10.1007/s13311-018-00679-z.

    PMID: 30341596
  4. 4

    FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

    Weeden T, Picariello T, Quinn B, et al.

    Communications medicine 2025; (5(1)):22 doi:10.1038/s43856-025-00733-w.

    PMID: 39827287
  5. 5

    Self-Assembled Antibody-Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides.

    Zhou L, Bi J, Chang S, et al.

    Angewandte Chemie (International ed. in English) 2025; (64(3)):e202415272 doi:10.1002/anie.202415272.

    PMID: 39325927
  6. 6

    CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.

    van Agtmaal EL, André LM, Willemse M, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2017; (25(1)):24-43 doi:10.1016/j.ymthe.2016.10.014.

    PMID: 28129118
  7. 7

    Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.

    Marsh S, Hanson B, Wood MJA, et al.

    Molecular therapy : the journal of the American Society of Gene Therapy 2020; (28(12)):2527-2539 doi:10.1016/j.ymthe.2020.10.005.

    PMID: 33171139
  8. 8

    CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy.

    Amendola M, Brusson M, Miccio A

    Stem cells translational medicine 2022; (11(10)):1003-1009 doi:10.1093/stcltm/szac064.

    PMID: 36048170
  9. 9

    Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.

    Bassez G, Audureau E, Hogrel JY, et al.

    Brain : a journal of neurology 2018; (141(10)):2855-2865 doi:10.1093/brain/awy231.

    PMID: 30169600
  10. 10

    Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients.

    Ravel-Chapuis A, Duchesne E, Jasmin BJ

    The Journal of physiology 2022; (600(14)):3249-3264 doi:10.1113/JP282725.

    PMID: 35695045
  11. 11

    Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening.

    Jenquin JR, O'Brien AP, Poukalov K, et al.

    iScience 2022; (25(5)):104198 doi:10.1016/j.isci.2022.104198.

    PMID: 35479399
  12. 12

    Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries.

    Higgs C, Hilbert JE, Wood L, et al.

    Frontiers in neurology 2019; (10()):1071 doi:10.3389/fneur.2019.01071.

    PMID: 31681146
  13. 13

    International collaboration to improve knowledge on myotonic dystrophy type 2.

    Peric S, Ivanovic V, Ashley EJ, et al.

    Journal of neuromuscular diseases 2024; (11(6)):1229-1237 doi:10.1177/22143602241290353.

    PMID: 39973464
  14. 14

    Health-related quality of life, pain, and fatigue in myotonic dystrophy type 2: a 13-year follow-up study.

    Damen MJ, Mul K, van Engelen BGM, et al.

    Disability and rehabilitation 2025; 1-8 doi:10.1080/09638288.2025.2571068.

    PMID: 41173243
  15. 15

    Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease.

    Wood L, Bassez G, Bleyenheuft C, et al.

    Orphanet journal of rare diseases 2018; (13(1)):155 doi:10.1186/s13023-018-0889-0.

    PMID: 30185236
  16. 16

    Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.

    Wu J, Wang C, Toh S, et al.

    Pharmacoepidemiology and drug safety 2020; (29(10)):1213-1218 doi:10.1002/pds.4962.

    PMID: 32003065

This page discusses experimental therapies and clinical trials for informational purposes only. Always consult your neurologist or care team before making changes to your treatment plan or pursuing clinical trial enrollment.

Stay up to date

Get notified when new research about Myotonic dystrophy is published.

No spam. Unsubscribe anytime.